XML 74 R40.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaborative and Other Relationships Collaborative and Other Relationships (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Revenues from anti-CD20 therapeutic programs |
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA | $ | 359.0 |  |  | $ | 347.5 |  |  | $ | 708.6 |  |  | $ | 671.0 |
Other revenues from anti-CD20 therapeutic programs | 131.4 |  |  | 49.6 |  |  | 225.0 |  |  | 66.7 |
Total revenues from anti-CD20 therapeutic programs | $ | 490.4 |  |  | $ | 397.1 |  |  | $ | 933.6 |  |  | $ | 737.7 |
Summary of Activity Related to Aducanumab Collaboration |
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Total development expense incurred by the collaboration related to the advancement of aducanumab | $ | 76.5 |  |  | $ | 74.6 |  |  | $ | 140.0 |  |  | $ | 128.9 |
Biogen's share of aducanumab development expense reflected in research and development expense in our condensed consolidated statements of income | $ | 65.0 |  |  | $ | 74.6 |  |  | $ | 128.5 |  |  | $ | 128.9 |
Total sales and marketing expense incurred by the collaboration related to the advancement of aducanumab | $ | 14.0 |  |  | $ | 4.8 |  |  | $ | 21.2 |  |  | $ | 9.8 |
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense our condensed consolidated statements of income | $ | 9.2 |  |  | $ | 4.8 |  |  | $ | 13.9 |  |  | $ | 9.8 |
Summary of Activity Related to E2609 and BAN2401 Collaboration |
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017 |  | 2018 |  | 2017
Total development expense incurred by the collaboration related to the advancement of BAN2401 and E2609 | $ | 54.6 |  |  | $ | 29.5 |  |  | $ | 111.1 |  |  | $ | 66.7 |
Biogen's share of BAN2401 and E2609 development expense reflected in research and development expense in our condensed consolidated statements of income | $ | 27.3 |  |  | $ | 14.7 |  |  | $ | 55.5 |  |  | $ | 33.3 |

X
- Definition Revenues from anti-CD20 therapeutic programs collaboration footnote [Table Text Block] + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramscollaborationfootnoteTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration